Assessment and Management of Pain in the Terminally Ill

Primary Care - Clinics in Office Practice

Volumn 38, Issue 2, 2011, Pages 195-223

  Dalal, Shalini ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Opioids; Pain management; Palliative care; Terminal illness

Indexed keywords

ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CANNABINOID; CARBAMAZEPINE; CHLORPROMAZINE; CODEINE; CORTICOSTEROID; FENTANYL; GABAPENTIN; HALOPERIDOL; HYDROCODONE; HYDROMORPHONE; METHADONE; MIDAZOLAM; MORPHINE; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; OXYMORPHONE; PARACETAMOL; PETHIDINE; PREGABALIN; TAPENTADOL; TIAGABINE; TOPIRAMATE; TRAMADOL; UNINDEXED DRUG;

AGRANULOCYTOSIS; APLASTIC ANEMIA; AUDITORY HALLUCINATION; BEDTIME DOSAGE; BLEEDING; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; BONE PAIN; CANCER PAIN; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DIZZINESS; DRUG CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILY DECISION MAKING; FIBROMYALGIA; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HUMAN; HYPONATREMIA; INFLAMMATION; KIDNEY DYSFUNCTION; MEDICAL ASSESSMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHIC PAIN; NEUROTOXICITY; PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; PATIENT COMPLIANCE; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SCREENING TEST; SEDATION; SEIZURE; SIDE EFFECT; SKIN DISEASE; TERMINAL DISEASE; TERMINALLY ILL PATIENT; TREATMENT PLANNING; UNSTEADINESS; VISUAL HALLUCINATION; VOMITING;

ANALGESICS; COGNITION DISORDERS; COMORBIDITY; COMPLEMENTARY THERAPIES; DRUG ADMINISTRATION ROUTES; HUMANS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; SEVERITY OF ILLNESS INDEX; TERMINALLY ILL; UNITED STATES;

EID: 79957668556     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2011.03.004     Document Type: Review

References (110)

1. Xu J., Kochanek K.D., Murphy S.L., et al. Deaths: final data for 2007 2010, National Center for Health Statistic, Hyattsville (MD).
2. Gruneir A., Mor V., Weitzen S., et al. Where people die: a multilevel approach to understanding influences on site of death in America. Med Care Res Rev 2007, 64(4):351-378.
3. Teno J.M., Weitzen S., Fennell M.L., et al. Dying trajectory in the last year of life: does cancer trajectory fit other diseases?. J Palliat Med 2001, 4(4):457-464.
4. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995, 274(20):1591-1598.
5. Hogan C., Lunney J., Gabel J., et al. Medicare beneficiaries' costs of care in the last year of life. Health Aff (Millwood) 2001, 20(4):188-195.
6. Goodlin S.J., Winzelberg G.S., Teno J.M., et al. Death in the hospital. Arch Intern Med 1998, 158(14):1570-1572.
7. Teno J.M., Clarridge B.R., Casey V., et al. Family perspectives on end-of-life care at the last place of care. JAMA 2004, 291(1):88-93.
8. Lesage P., Portenoy R.K. Trends in cancer pain management. Cancer Control 1999, 6(2):136-145.
9. Cleeland C.S., Gonin R., Hatfield A.K., et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994, 330(9):592-596.
10. O'Mahony S., Goulet J., Kornblith A., et al. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. J Pain Symptom Manage 2005, 29(5):446-457.
11. Inouye S.K. The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients. Am J Med 1994, 97(3):278-288.
12. Brink-Huis A., van Achterberg T., Schoonhoven L. Pain management: a review of organisation models with integrated processes for the management of pain in adult cancer patients. J Clin Nurs 2008, 17(15):1986-2000.
13. Morrison R.S., Dietrich J., Meier D.E. America's Care of serious illness: a state-by-state report card on access to palliative care in our nation's hospitals 2008, Center to Advance Palliative Care, New York.
14. Turk D.C., Monarch E.S., Williams A.D. Cancer patients in pain: considerations for assessing the whole person. Hematol Oncol Clin North Am 2002, 16(3):511-525.
15. Saunders C. The management of terminal malignant disease 1978, Edward Arnold, London. 1st edition.
16. Bruera E., Kuehn N., Miller M.J., et al. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991, 7(2):6-9.
17. Fainsinger R.L., Fairchild A., Nekolaichuk C., et al. Is pain intensity a predictor of the complexity of cancer pain management?. J Clin Oncol 2009, 27(4):585-590.
18. Wagner-Johnston N.D., Carson K.A., Grossman S.A. High outpatient pain intensity scores predict impending hospital admissions in patients with cancer. J Pain Symptom Manage 2010, 39(2):180-185.
19. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999, 96(7):3540-3545.
20. Fishman B., Pasternak S., Wallenstein S.L., et al. The memorial pain assessment card. A valid instrument for the evaluation of cancer pain. Cancer 1987, 60(5):1151-1158.
21. Daut R.L., Cleeland C.S., Flanery R.C. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983, 17(2):197-210.
22. Quality improvement guidelines for the treatment of acute pain and cancer pain. American Pain Society Quality of Care Committee. JAMA 1995, 274(23):1874-1880.
23. Gordon D.B., Dahl J.L., Miaskowski C. American pain society recommendations for improving the quality of acute and cancer pain management: American pain society quality of care task force. Arch Intern Med 2005, 165(14):1574-1580.
24. Lawlor P.G., Gagnon B., Mancini I.L., et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000, 160(6):786-794.
25. Minagawa H., Uchitomi Y., Yamawaki S., et al. Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer 1996, 78(5):1131-1137.
26. Association A.P. Delirium, dementia and amnestic and other cognitive disorders. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Assocation, Washington, DC.
27. Armstrong S.C., Cozza K.L., Watanabe K.S. The misdiagnosis of delirium. Psychosomatics 1997, 38(5):433-439.
28. Pereira J., Hanson J., Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer 1997, 79(4):835-842.
29. Breitbart W., Rosenfeld B., Roth A., et al. The Memorial Delirium Assessment Scale. J Pain Symptom Manage 1997, 13(3):128-137.
30. Ferrell B.R. The impact of pain on quality of life. A decade of research. Nurs Clin North Am 1995, 30(4):609-624.
31. Closs S.J., Barr B., Briggs M., et al. A comparison of five pain assessment scales for nursing home residents with varying degrees of cognitive impairment. J Pain Symptom Manage 2004, 27(3):196-205.
32. Herr K., Bjoro K., Decker S. Tools for assessment of pain in nonverbal older adults with dementia: a state-of-the-science review. J Pain Symptom Manage 2006, 31(2):170-192.
33. Desbiens N.A., Mueller-Rizner N. How well do surrogates assess the pain of seriously ill patients?. Crit Care Med 2000, 28(5):1347-1352.
34. Redinbaugh E.M., Baum A., DeMoss C., et al. Factors associated with the accuracy of family caregiver estimates of patient pain. J Pain Symptom Manage 2002, 23(1):31-38.
35. Allen R.S., Haley W.E., Small B.J., et al. Pain reports by older hospice cancer patients and family caregivers: the role of cognitive functioning. Gerontologist 2002, 42(4):507-514.
36. Coyle N., Adelhardt J., Foley K.M., et al. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 1990, 5(2):83-93.
37. Homsi J., Walsh D., Rivera N., et al. Symptom evaluation in palliative medicine: patient report vs systematic assessment. Support Care Cancer 2006, 14(5):444-453.
38. Stromgren A.S., Groenvold M., Pedersen L., et al. Does the medical record cover the symptoms experienced by cancer patients receiving palliative care? A comparison of the record and patient self-rating. J Pain Symptom Manage 2001, 21(3):189-196.
39. Glover J., Dibble S.L., Dodd M.J., et al. Mood states of oncology outpatients: does pain make a difference?. J Pain Symptom Manage 1995, 10(2):120-128.
40. Ahles T.A., Blanchard E.B., Ruckdeschel J.C. The multidimensional nature of cancer-related pain. Pain 1983, 17(3):277-288.
41. World Health Organization Cancer pain relief 1996, World Health Organization, Geneva (Switzerland). 2nd edition.
42. Hanks G.W., Conno F., Cherny N., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001, 84(5):587-593.
43. Jacox A., Carr D.B., Payne R., et al. Management of cancer pain. Clinical practice guideline no. 9 AHCPR Pub. No. 94-0592 1994, Agency for Health Care and Research, US Department of Health and Human Services, Public Health Service, Rockville (MD).
44. McNicol E., Strassels S.A., Goudas L., et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005, 1. CD005180.
45. Eisenberg E., Berkey C.S., Carr D.B., et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994, 12(12):2756-2765.
46. Mercadante S., Porzio G., Ferrera P., et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006, 31(3):242-247.
47. Marinangeli F., Ciccozzi A., Leonardis M., et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004, 27(5):409-416.
48. Woolf C.J. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004, 140(6):441-451.
49. Sabino M.A., Ghilardi J.R., Jongen J.L., et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002, 62(24):7343-7349.
50. Davies N.M., Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 2004, 7(3):332-336.
51. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286(8):954-959.
52. NIH Office of Communications Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial Available at:, Accessed October 19, 2006. http://www.nih.gov/news/pr/dec2004/od-20.htm.
53. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338(11):727-734.
54. Helm S., Trescot A.M., Colson J., et al. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician 2008, 11(2):225-235.
55. Kaltenback B.L., Becker A. Use of opioids in adults with chronic cancer pain. Health Care 2002, 1:1-7.
56. Houde R. Clinical analgesic studies of hydromorphone. Advances in pain research and therapy 1986, 129-135. Raven Press, New York. K. Foley, C. Inturrisi (Eds.).
57. Gabrail N.Y., Dvergsten C., Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004, 20(6):911-918.
58. Walsh D., Donnelly S., Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000, 8(3):175-179.
59. Fainsinger R.L., Nekolaichuk C.L., Lawlor P.G., et al. A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage 2005, 29(3):224-237.
60. Mercadante S., Casuccio A., Agnello A., et al. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol 1998, 16(11):3656-3661.
61. Bruera E., Palmer J.L., Bosnjak S., et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004, 22(1):185-192.
62. Mercadante S., Porzio G., Ferrera P., et al. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008, 12(8):1040-1046.
63. Walker P.W., Palla S., Pei B.L., et al. Switching from methadone to a different opioid: what is the equianalgesic dose ratio?. J Palliat Med 2008, 11(8):1103-1108.
64. Bamigbade T.A., Davidson C., Langford R.M., et al. Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. British Journal of Anaesthesia 1997, 79(3):352-356.
65. Chizh B.A., Headley P.M., Tzschentke T.M. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 2001, 22(12):636-642.
66. Bruera E., Pereira J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain 1997, 69(1-2):199-201.
67. Adair J.C., el-Nachef A., Cutler P. Fentanyl neurotoxicity. Ann Emerg Med 1996, 27(6):791-792.
68. Fishbain D.A., Rosomoff H.L., Rosomoff R.S. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 1992, 8(2):77-85.
69. Porter J., Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980, 302(2):123.
70. McQuay H.J. Opioid use in chronic pain. Acta Anaesthesiol Scand 1997, 41(1 Pt 2):175-183.
71. McNicol E., Horowicz-Mehler N., Fisk R.A., et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003, 4(5):231-256.
72. Allan L., Hays H., Jensen N.H., et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001, 322(7295):1154-1158.
73. Staats P.S., Markowitz J., Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J 2004, 97(2):129-134.
74. Bruera E., Neumann C.M. Management of specific symptom complexes in patients receiving palliative care. CMAJ 1998, 158(13):1717-1726.
75. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999, 86(9):1856-1866.
76. Bowsher D. Paradoxical pain. BMJ 1993, 306(6876):473-474.
77. Mercadante S., Ferrera P., Villari P., et al. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 2003, 26(2):769-775.
78. Szarvas S., Harmon D., Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth 2003, 15(3):234-239.
79. Moryl N., Coyle N., Foley K.M. Managing an acute pain crisis in a patient with advanced cancer: "this is as much of a crisis as a code" JAMA 2008, 299(12):1457-1467.
80. Bruera E, Rico M, Bertolino M, et al. A prospective, open study of oral methadone in the treatment of cancer pain. In: Devor M, Rowbotham M, Weisenfeld-Hallin Z, editions. Proceedings of the 9th World Congress on Pain. Seattle (WA): IASP Press; 2000. p. 957-63.
81. Backonja M., Beydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280(21):1831-1836.
82. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998, 280(21):1837-1842.
83. Caraceni A., Zecca E., Martini C., et al. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 1999, 17(6):441-445.
84. Petrenko A.B., Yamakura T., Baba H., et al. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003, 97(4):1108-1116.
85. Bell R., Eccleston C., Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2003, 1. CD003351.
86. Ross J.R., Saunders Y., Edmonds P.M., et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003, 327(7413):469.
87. Wong R., Wiffen P.J. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002, 2. CD002068.
88. Body J.J. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001, 28(4 Suppl 11):49-53.
89. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98(8):1735-1744.
90. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23(34):8580-8587.
91. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23(6):826-836.
92. Feuer D.J., Broadley K.E. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev 2000, 2. CD001219.
93. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain 1999, 82(2):199-205.
94. Fox A., Kesingland A., Gentry C., et al. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001, 92(1-2):91-100.
95. Kehl L.J., Hamamoto D.T., Wacnik P.W., et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 2003, 103(1-2):175-186.
96. Campbell F.A., Tramer M.R., Carroll D., et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001, 323(7303):13-16.
97. Abrams D.I., Jay C.A., Shade S.B., et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007, 68(7):515-521.
98. Svendsen K.B., Jensen T.S., Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004, 329(7460):253.
99. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006, 53(8):769-775.
100. NSativex [product information]. Toronto, Canada: Bayer Inc; 2008.
101. Tilden V.P., Drach L.L., Tolle S.W. Complementary and alternative therapy use at end-of-life in community settings. J Altern Complement Med 2004, 10(5):811-817.
102. Demmer C. A survey of complementary therapy services provided by hospices. J Palliat Med 2004, 7(4):510-516.
103. Kozak L.E., Kayes L., McCarty R., et al. Use of complementary and alternative medicine (CAM) by Washington State hospices. Am J Hosp Palliat Care 2008, 25(6):463-468.
104. Hwang S.S., Chang V.T., Kasimis B. Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time. J Pain Symptom Manage 2002, 23(3):190-200.
105. Medicine AAoHaP AAHPM position statement on sedation at the end of life 2006, American Academy of Hospice and Palliative Medicine, Available at:, Accessed March 2, 2011. http://www.aahpm.org/positions/default/sedation.html.
106. Vacco v Quill, 117 Wests Supreme Court Report. 2293, 2312 (1997).
107. Washington v Glucksberg, 117 Wests Supreme Court Report. 2258, 2293 (1997).
108. American Academy of Hospice and Palliative Medicine AAHPM position statement: statement on palliative sedation Available at:, Accessed September 17, 2010. http://www.aahpm.org/positions/sedation.html.
109. Hospice and Palliative Nurses Association HPNA position statement: palliative sedation at end of life Available at:, Accessed September 17, 2010. http://www.hpna.org/DisplayPage.aspx?Title=Position%20Statements.
110. Sulmasy D.P., Pellegrino E.D. The rule of double effect: clearing up the double talk. Arch Intern Med 1999, 159(6):545-550.